Cite
HARVARD Citation
Shor, R. et al. (2022). The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings. Molecular oncology. 16 (1), pp. 130-147. [Online].